//Wataru Akahata

About Wataru Akahata

This author has not yet filled in any details.
So far Wataru Akahata has created 3 blog entries.

VLP Therapeutics Announces Issuance of US Patent for Dengue Vaccine


October 18, 2018 Gaithersburg, MD -- VLP Therapeutics announced the issuance of US Patent 10,098,943 titled, “Flavivirus virus-like particle” on October 16, 2018. This patent supports VLP Therapeutics’ Native Virus Modification virus-like particle platform on which the Company’s dengue vaccine is based and which could form the basis for other flavivirus vaccines. The patent relates

VLP Therapeutics is Recognized by the Government of Japan (Cabinet Office) “Comprehensive Strategy on Science, Technology and Innovation for 2017”


VLP Therapeutics was recently recognized as one of eleven companies that exemplify Japan’s commitment to Innovation as outlined in the 2017 Comprehensive Strategy on Science, Technology and Innovation. In 2017 the Cabinet Office of the Government of Japan published a Comprehensive Strategy on Science, Technology and Innovation which outlined a strategy to enhance Japan’s industrial

VLP Therapeutics announces the Issuance of US Patent #9,969,986


Patent covers a virus-like particle comprising a viral structural protein comprising modified envelope protein E3 Gaithersburg, Md. — May 18, 2018 — VLP Therapeutics, LLC. (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and new cancer therapies, announced that the U.S. Patent and Trademark Office has issued US